MAWANI Adding the Shipping Service "FRS1" by "CSTAR LINE" to Jeddah Islamic Port
The new shipping service links Jeddah Islamic Port with five regional and global ports, including Ningbo, Shanghai, and Nansha in China, Aqaba in Jordan, and Ain Sokhna in Egypt, with a handling capacity of up to 2,000 TEUs.
This step aligns with Mawani's ongoing efforts to improve the Kingdom's standing in global performance indicators and support national export movement, in line with the objectives of the National Transport and Logistics Strategy, to solidify the Kingdom's standing as a global logistics hub bridging the three continents.
It is worth noting that Jeddah Islamic Port features a high handling capacity of 130 million tons, and advanced logistics services through 62 multipurpose berths, in addition to several specialized terminals and modern facilities, including two container terminals with a handling capacity of 7.5 million TEUs, two general cargo terminals, two dry docks for ship repair and marine unit maintenance, and a group of marine service berths.
Photo - https://mma.prnewswire.com/media/2735719/Mawani.jpgLogo - https://mma.prnewswire.com/media/2702111/5425233/The_Saudi_Ports_Authority_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/mawani-adding-the-shipping-service-frs1-by-cstar-line-to-jeddah-islamic-port-302510566.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Betterhomes Reports Dubai Residential Property Market Remains a Global Magnet in H1 2025 with Sales Surging
DUBAI, UAE, July 23, 2025 /PRNewswire/ -- Dubai's residential real estate market continues to defy global headwinds, delivering another record-breaking performance in the first half of 2025. According to the newly released Shaping Skylines Q2 2025 Dubai Residential Real Estate Market Report by Betterhomes, total residential sales reached AED 151.8 billion, a 46% year-on-year increase in value and a 25% rise in transaction volumes, with 50,485 units sold. The report highlights Dubai's continued ascent as one of the world's most dynamic real estate destinations, supported by a growing population seeking Dubai homes for sale, investor-friendly legislation, and a robust development pipeline. Momentum Continues Across Segments Compared to Q1, residential sales grew 33% in value and 19% in volume, underlining strong market momentum. The prime residential segment recorded a new benchmark with 1,417 luxury transactions in Q2, a 67% quarter-on-quarter jump and a 113% increase year-on-year which confirms a rising global appeal of luxury off-plan property for sale in Dubai among ultra-high-net-worth buyers. "Q3 is shaping up to be an exciting phase for Dubai's property market," said Christopher Cina, Director of Sales at Betterhomes. "With around 20,000 new units already delivered and another 70,000 expected by year-end, the city is well-positioned to meet rising demand from investors and end-users alike." Supply Expands, Prices Hold Strong Dubai saw over 20,000 new units delivered in H1 2025, with Jumeirah Village Circle (JVC) leading completions at 20%, followed by Sobha Hartland (11%) and Mohammed Bin Rashid City (8%). Looking ahead, over 200,000 new units are projected through 2027 reflecting developer confidence in Dubai's long-term growth. Despite the influx of supply, average property prices continue to rise, reaching AED 1,582 per square foot, a 6% increase from H2 2024 and up 3% from Q1 2025. Prices are now 18% higher year-on-year and 90% above the pandemic-era low of AED 833 per square foot. Investor Activity and Cash Deals on the Rise The report also revealed a strong resurgence in investor activity, with investors accounting for 58% of all transactions in Q2, up from 50% in Q1. Meanwhile, end-user activity dropped to 42%, as buyers sought rental income and capital appreciation in a high-demand market. Cash buyers dominated the market in Q2, representing 52% of transactions, up from 42% in Q1. Mortgage deals fell to 48%, indicating an increasingly liquid buyer base, driven by high-net-worth individuals and international investors seeking swift deal closures. Global Buyer Shifts Reflect Dubai's Expanding Reach The UK overtook India to become the leading buyer nationality in Q2, driven by a 56% quarterly surge in transactions. India and Pakistan retained second and third positions, respectively, while Poland made its debut in the top five. Notably, Russia dropped out of the top 10 for the first time, with Ireland climbing to sixth. As Dubai continues to draw global interest, particularly from European buyers, its property market stands firm as one of the most attractive and resilient investment destinations worldwide. View original content: SOURCE Betterhomes 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Forbes
6 hours ago
- Forbes
Israeli Startups Using AI To Accelerate Drug Discovery
AI Aiding in drug discovery Israel-based AION Labs wants to drive AI to revolutionize pharmaceutical drug discovery and development. AION is an innovative venture that brings together pharmaceutical heavyweights—Pfizer, AstraZeneca, Teva, and Merck—with entrepreneurial scientists, technology leaders, and successful investors. 'We are a venture studio that builds startups using computational technologies and artificial intelligence to unleash new capabilities to discover and develop new drugs with a venture model that we invented,' says Mati Gill, CEO of AION. This unique collaboration addresses a costly endeavor that is crucial to the quality of our lives. It takes $5 billion and ten years to bring a new drug to market. The world's top 20 pharmaceutical companies collectively spent $145 billion on R&D in 2022-23, according to a recent Deloitte report, which also noted 'AI is yet to become a 'game-changer' in pharma R&D.' A more comprehensive survey of 4,191 pharmaceutical companies worldwide, published in Nature Reviews Drug Discovery, found that they spent $276 billion on R&D in 2021. These R&D expenses have increased tenfold since the 1980s (after adjusting for inflation), and pharmaceutical companies now allocate approximately 25% of their revenue to R&D, nearly double the share seen in the early 2000s, according to CB Insights. 'AI could potentially cut years off the discovery process and compress clinical trial times by up to 30%. This would accelerate the delivery of new treatments to patients, unlock novel treatment approaches, and enable more personalized medicine,' noted CBI. Another CBI report, on the AI readiness of pharmaceutical companies, highlighted the importance of external collaboration, 'as breakthrough innovations increasingly emerge from partnerships rather than internal development alone.' Gill predicts that by 2030, the first truly AI-designed drugs will reach regulatory approval. He believes that Israel is uniquely positioned to be a leading ecosystem in transforming the global biotech and pharmaceutical landscape, given its strengths in multidisciplinary scientific discovery, entrepreneurial innovation, computational biology and big data analysis, as well as a robust and integrated healthcare system, and strong government support. 'For the first time, Israel's strengths are coinciding with what the future of the industry is going to be,' says Gill. There are three core principles behind every startup that AION selects and supports, explains Gill: they address a validated, well-defined, industry-wide problem statement; there's a multidisciplinary team that has expertise in both AI and biology and a technology that can solve that problem statement; and that at least one of AION' pharmaceutical partners is willing to commit to working with the startup to initially develop their technology and conduct with them a proof-of-concept at an early stage. The R&D teams of AION Labs' partners help select the specific industry-wide challenges to focus on and the technologies and scientist-led startups that will develop the solutions. To accomplish that, AION has established two tracks, one starting with the problem statement and the other starting with the technology. DenovAI is an example of starting with the problem statement. Is it possible to design proteins 'de novo' or completely from scratch? 'We ran a challenge and had 15 great candidates,' recounts Gill. 'We selected a senior scientist who had developed a technology called AlphaDesign that is basically doing the inverse of the famous AlphaFold.' The startup recently demonstrated its ability to generate new proteins with measurable, targeted function. Its AI-based platform for rapid de novo antibody discovery could reduce the discovery process from months to days, and broaden the scope of therapy to a wide range of diseases. Cassidy Bio is an example of starting with the technology. It is using large language models or LLMs to design new guide RNAs, unlocking the capability of gene therapy in a scalable and precise manner. Guide RNAs or gRNAs serve as the 'GPS' for CRISPR systems, directing the editing machinery to precise genetic targets. The design of gRNAs plays a critical role in determining both the efficacy and safety of gene-editing therapeutics. Professor Ayal Hendel of Israel's Bar-Ilan University, a leading expert in genome editing and gene therapy, teamed up with two experienced entrepreneurs to establish the startup. With AION Labs' help, they raised $8 million in seed funding and are working with AstraZeneca to validate their technology. Based on proprietary, clinically relevant genomic data generation, state-of-the-art predictive algorithms, and rigorous wet lab validation, Cassidy Bio is developing the first comprehensive predictive platform based on LLMs for gRNA design. Unlike the data driving AI consumer applications, which is mostly based on internet-scraped data, pharmaceutical data is proprietary data. AION Labs' unique collaborative model provides access to pharmaceutical firms' R&D teams and their data, along with a secure sharing environment facilitated by AION's tech partner, Amazon's cloud service. This means the pharmaceutical companies can share their proprietary data with the startups in AION Labs' portfolio, but not with each other. AION Labs is also a member of Israel's 8400 The Health Network. This network was founded in 2017 on the premise that HealthTech is Israel's next economic growth engine and that Israel has what it takes to become a game-changing player in the global HealthTech revolution, according to its CEO, Ari Strasberg. To date, the non-profit organization has developed numerous programs and national initiatives, ranging from HealthIL, which bridges the gap between healthcare systems and technology by facilitating over 1,300 pilots and implementing 160 projects, to Helix, which strengthens the working relationships between 46 top U.S. and Israeli HealthTech leaders. The organization has been very successful, says Strasberg, in creating a public-private partnership, connecting government programs with 'the needs of the ecosystem.' Another success story is the development of FIRE, the data interoperability standard used by the healthcare systems in Israel. Going forward, Strasberg would like 8400 to play a major role in increasing the number of very successful Israeli HealthTech startups. 'We have a few, but not enough,' says Strasberg. 'We need to have a few blockbuster ones that carry the entire ecosystem with them.'
Yahoo
6 hours ago
- Yahoo
Joao Felix set for Al-Nassr medical after Chelsea accept £26m offer featuring 'add-ons and heavy sell-on clause' in order to meet Blues' asking price
Felix authorised to travel to Saudi Arabia for medical Add-ons and 'heavy sell-on clause' make up large part of deal Chelsea value Portuguese at €50m Follow GOAL on WhatsApp! 🟢📱 WHAT HAPPENED? Fabrizio Romano reports the deal includes "add-ons and heavy sell-on clause" in order to meet Chelsea's valuation. The Stamford Bridge club had slapped a €50m price-tag on the 24-year-old. THE BIGGER PICTURE The former prodigy has been given the green light to travel to Saudi Arabia ahead of the deal. It bring's Felix's second spell with the west London club to an end. Across this latest stint, and an initial period on loan from Atletico Madrid in 2023, Felix has made 40 appearances, and scored 11 goals for Chelsea. He spent the second half of the 2024-25 season on loan at AC Milan. DID YOU KNOW? This is the latest change of scene for a player that promised so much early on in his career. The guaranteed €30m fee brings the total disclosed spending by clubs on Felix to €209m; €225.5m, when including loan fees. WHAT NEXT FOR FELIX? The 24-year-old needs regular first-team football to re-capture the form that made him one of world football's hottest properties. Perhaps a couple of seasons linking up with his compatriot Cristiano Ronaldo, could be the impetus Felix needs to extract more from his undeniable talents.
